Complete Response to Immunotherapy in Stage IV Lung Cancer
A 51-year-old man with stage IV lung cancer and brain metastasis achieved complete response to immunotherapy after WBRT.
Complete the form below to unlock access to ALL audio articles.
Summary
A case report highlights a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis who received whole brain radiotherapy followed by immune checkpoint inhibitor treatment. The patient achieved complete response, with overall survival at 87 months and progression-free survival at 73 months, maintaining quality of life.
Key Takeaways
A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis.”
As highlighted in the abstract of this report, approximately 20% of lung cancer patients have brain metastases at diagnosis, which is associated with a worse prognosis and negatively impacts quality of life. The emergence of new systemic treatment options, such as immune checkpoint inhibitors (ICI) and targeted therapies, has changed the prognosis for stage IV lung cancer patients. However, the impact of treatment sequencing—both local and systemic—in patients with stage IV lung cancer and brain metastases remains unclear.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREEResearchers Mafalda Costa and Helena Magalhães from the Department of Medical Oncology, Hospital Pedro Hispano in Matosinhos, Portugal present the case of a 51-year-old man diagnosed with stage IV non-small cell lung cancer (NSCLC) and brain metastasis. After undergoing whole brain radiotherapy (WBRT), the patient achieved both intracranial and extracranial complete response following second-line treatment with an immune checkpoint inhibitor. Currently, he has an overall survival of 87 months and a progression-free survival of 73 months, maintaining an optimal quality of life.
"We hypothesized that treatment sequencing of WBRT and immunotherapy could explain this unexpected outcome.”
Reference: Costa M, Magalhães H. Complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer with brain metastasis. Oncoscience. 2024;11:92-98. doi: 10.18632/oncoscience.609
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.
